MWNA
GRCL

Marshall Wace North America’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Marshall Wace North America’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.14M Sell
82,348
-21
-0% -$248 ﹤0.01% 877
2021
Q2 		$1.07M Sell
82,369
-1,191
-1% -$15.9K ﹤0.01% 992
2021
Q1 		$1.29M Buy
+83,560
New +$1.97M 0.01% 956

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace North America's GRCL Position: Q3 2021 in Review

Marshall Wace North America reduced its Gracell Biotechnologies Inc. American Depositary Shares (GRCL) stake by 0.03% in Q3 2021, selling an estimated $248 and leaving 82,348 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #877.

Marshall Wace North America first reported a position in GRCL in Q1 2021 and has held it in 3 quarters since. The position peaked at $1.29M in Q1 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q3 2021.

  • Marshall Wace North America held 82,348 shares of Gracell Biotechnologies Inc. American Depositary Shares worth $1.14M as of Q3 2021.
  • Marshall Wace North America sold 21 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2021, an estimated $248.
  • Gracell Biotechnologies Inc. American Depositary Shares made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #877 holding.
  • Marshall Wace North America first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and has held it in 3 quarters since.
  • Marshall Wace North America's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1.29M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.